"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising altogether an amino acid sequence that is at least 95 % identical to an seq id no : 76 ; b ) a heavy chain complementarity determining region region 2 ( hcdr2 ) comprising an amino acid tag sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity identifying determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that each is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody group binds an epitope comprising amino acid residue id 238 of hpcsk9 ( seq id id no : 2 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that only specifically binds hpcsk9, comprising : an a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least of 95 % identical to seq id no : 80 ; d ) within a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least to 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( specifically lcdr3 ) comprising an amino aromatic acid sequence that is at least 95 % identical to seq abd id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of which the antibody binds an epitope comprising amino amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an artificial antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining in region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that likely is at least 95 % identical to seq id identification no : 78 ; c ) a similar heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining within region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising only an amino acid sequence that is at any least 95 % identical to the seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising the amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of or an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity identification determining region 1 ( hcdr1 ) comprising an all amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an entire amino acid sequences sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain neutral complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 21 86 ; and f ) a light chain complementarity determining region region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical overall to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or other antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid extract sequence sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy amino chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq identity id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) potentially comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) comprising a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining sequence region 2 ( lcdr2 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody group binds an epitope comprising amino and acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq ix id no : 76 ; b ) a heavy chain secondary complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % basically identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % also identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an identifiable amino acid sequence that is at least 95 % identical identical to seq id id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least nearly 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical as to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id token no : 755 ).","238, 755"
"an antibody or antigen - binding data fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a distinct heavy chain complementarity determining determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; thus d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % fully identical to seq id ip no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical as to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 88. 2. the antibody entry or antigen - binding sample fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - specifically binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy single chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid residues sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) thus comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising principally an antibody amino acid sequence that is at least 95 % identical to seq ida id no : 10 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising predominantly an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id ir no : 755 ).","238, 755"
"an antibody or other antigen - binding fragment of an antibody form that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity position determining gene region 1 ( near hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( like hcdr3 ) comprising an amino acid peptide sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical relative to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( type lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the same antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that sometimes specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is usually at least 95 % identical to seq shy id no : 80 ; d ) wherein a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain regional complementarity determining region 2 ( lcdr2 ) comprising an amino or acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain central complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. alternatively the antibody or antigen - binding fragment of an antibody of claim 1, wherein the primary antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 85 755 ).","238, 755"
"an antibody component or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region zone 2 ( hcdr2 ) comprising an amino acid sequence that previously is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; then d ) contain a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at to least 95 % identical again to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence itself that is typically at least 95 % identical to seq id no : 88. 2. involve the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an initial amino acid sequence that is at least 95 % identical according to seq id accession no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising upon an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) and comprising an amino acid sequence that is approximately at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or other antigen - binding fragment composed of an antibody of claim 1, wherein both the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) containing a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is probably at least 95 % identical to hiv seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an individual amino acid sequence that likely is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining regional region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. plot 2. the antibody or antigen - binding protein fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue type 238 of an hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding identification fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( denoted hcdr1 ) comprising an amino acid sequence that is at which least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % virtually identical to seq id no : 78 ; c ) possessing a heavy chain complementarity determining region 3 ( hcdr3 ) comprising altogether an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a unique light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least to 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein wherein the antibody or antigen - binding fragment of whereby the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an independent antibody or antigen - binding fragment of an industrial antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid acid sequences sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least exactly 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that that is at least 95 % identical to seq id no : 88. 2. observe the special antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or a antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of the hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically strongly binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid primary sequence that is at any least 95 % identical to seq id no : 57 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % as identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is broadly at least 95 % identical with to his seq id no : 86 ; and f ) a determined light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid secondary sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of type an antibody that specifically binds with hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that generally is at least least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical relative to seq id no : 86 ; and f ) a light chain independent complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, and wherein the antibody or antigen - binding protein fragment of the antibody binds an epitope comprising amino acid residue â„– 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) itself a heavy chain complementarity determining region 2 ( hcdr2 ) again comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising comprises an amino acid sequence that is at least least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) again comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id identification no : 86 ; and f ) a light short chain complementarity determining region 3 ( lcdr3 ) also comprising an amino acid sequence that is at least 95 % identical to seq id no : 51 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id identity no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) forming a single heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; to b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is also at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) possibly comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; also e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to measured seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino protein acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of the claim 1, formed wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity coupling determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising prominently an incorporated amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( usually hcdr3 ) comprising an amino acid sequence that is at least as 95 % identical to seq id id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical exactly to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an extended amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid binding sequence that is at least 95 % identical to seq id no : 88. and 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a light heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % structurally identical to seq id and no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising additionally an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity ion determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light single chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding target fragment compose of an antibody of claim division 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 representative of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antibody antigen - binding fragment composed of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) as comprising an amino acid sequence that is at least 95 % equally identical to seq id no : 78 ; c ) a combined heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical identical to seq id no : 84 ; e ) a light chain complementarity identification determining region 2 ( lcdr2 ) comprising an amino acid sequence that typically is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. figure 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid sequences residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy long chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a native heavy chain complementarity determining region 3 ( hcdr3 ) either comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq as id no : 84 ; e ) a light chain complementarity determining region unit 2 ( lcdr2 ) comprising an amino acid sequence that is roughly at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to its seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody consists of claim 1, wherein the antibody or antigen - binding fragment 117 of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or specific antigen - binding fragment of solely an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq iii id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to an seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity bearing determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at... least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % that identical to seq id no : 88. 2. the resulting antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - carrier binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq iv id no : 755 ).","238, 755"
"an antibody or either antigen - binding fragment of an antibody type that specifically binds hpcsk9, comprising : a ) a heavy twin chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( commonly hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least as 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody recognizes or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the target antibody binds an epitope comprising amino acid residue 238 of binding hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : an a ) a heavy chain complementarity determining region region 1 ( hcdr1 ) comprising only an amino acid sequence that is at least 95 % identical to an seq id no : 76 ; or b ) a heavy chain protein complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least to 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; and d ) a light chain antibody complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope sequence comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that of specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq identity id no : 78 ; c ) a heavy chain complementarity authentication determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid peptide sequence that is at least 95 % identical to manufacturer seq identification id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least approximately 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of containing an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds through an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 86 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy base chain complementarity determining region position 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino organic acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 86 ; and f ) a second light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid recognition sequence that that perhaps is at least 95 % almost identical to seq id no : 87 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an initial antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, or comprising : a ) alternatively a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that alone is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least again 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least another 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) or a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid composition sequence that is at least 95 % identical to seq id no : 87 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the primary antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically physically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( or hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id h no : 78 ; c ) a heavy chain complementarity alignment determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( denoted lcdr1 ) comprising an amino acid sequence that is at least approximately 95 % identical to seq id s no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is itself at least 95 % identical to seq id no : 86 ; 2 and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds on an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid chain sequence that is at least 95 % almost identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that itself is at least 95 % nearly identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acidic acid sequence segment that is at least 95 % identical solely to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, includes wherein case the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue line 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( abbreviated hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 96 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is any at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is all at least 95 % identical to seq et id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % entirely identical to seq id no : 86 ; and f ) a light chain complementarity tag determining terminal region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id rd no : 94 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is externally at least 95 % identical to its seq id no : 76 ; b ) a heavy chain complementarity analysis determining region group 2 ( hcdr2 ) comprising an amino magnetic acid sequence that itself is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino charged acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the second antibody or antigen - binding fragment of an antibody of claim number 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) only comprising an intermediate amino acid sequence that is not at least 95 % identical to seq id no : 76 ; b ) a heavy chain intermediate complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region type 3 ( hcdr3 ) comprising an amino acid sequence that is not at least 95 % identical to seq id no : 80 ; d ) a light daisy chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % itself identical to seq id no : 86 ; and f ) a light chain complementarity determining region group 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding signal fragment of an antibody that specifically binds hpcsk9, comprising : a ) containing a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence there that is at least 95 % identical to a seq id tag no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 )... comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an intact amino acid sequence himself that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region area 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( as seq id no : 755 ).","238, 755"
"an antibody diagnostic or antigen - substrate binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) features a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least exactly 95 % identical to seq id no no : 78 ; c ) contains a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % perfectly identical to seq id no : 80 ; d ) a light light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acids acid sequence that is at any least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is not at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid substitution sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an abdominal amino acid sequence that is at least 95 % identical to the seq id no : 6 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence expansion that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) structurally comprising an amino acid sequence that is at least 95 % identical to seq id id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising approximately an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, contains wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"include an antibody or antigen - binding fragment of an antibody that otherwise specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence unit that is at least nearly 95 % approximately identical to seq id no : 76 ; plus b ) a similar heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity tag determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least nearly 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id ind no : 76 ; b ) a corresponding heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; a c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an essential amino acid sequence that is at least 95 % identical to seq id no : 4 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising thereof an amino acid dna sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody itself or antigen - binding fragment of the antibody binds an epitope repeat comprising amino acid sequence residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq ic id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least exactly 95 % or identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an active amino acid sequence that is at least 95 % identical to seq id no : 86 ; and 5 f ) a light cross chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. name 2. the antibody or antigen - binding fragment of an antibody of claim 1, comprise wherein the third antibody or antigen - binding fragment 218 of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an international antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that itself is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least a 95 % identical to existing seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical simply to seq id no : 84 ; e ) furthermore a light chain complementarity determining region 2 ( lcdr2 ) comprising an independent amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. and the antibody or antigen - binding fragment of an antibody of claim genus 1, wherein the antibody drug or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( standard hcdr3 ) comprising an amino acid sequence average that is at least 95 % identical out to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light novel chain complementarity analysis determining region 2 ( lcdr2 ) additionally comprising an amino acid sequence overall that is at least 95 % identical to seq id no : 86 ; 8 and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment remains of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"identifying an antibody or specific antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : or a ) a heavy chain antigen complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq iv id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that specifically is at least 95 % identical to complement seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. map 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein precisely the antibody or antigen - specific binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; also c ) a basic heavy chain chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to the seq id no : 80 ; d ) a light chain complementarity level determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) furthermore a simple light chain chain complementarity determining region 2 ( lcdr2 ) comprising an outer amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is each at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"for an antibody or antigen - binding fragment of of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at or least 95 % identical to seq id no : 78 ; plus c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : of 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid recognition sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid identification sequence that is at at least 95 % identical to seq id no : 86 ; 6 and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment includes of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, usually comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( sr hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq sr id no : 78 ; b c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence sequence that is at least something 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq sd id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 85 88. 2. examine the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 inclusive of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of either an antibody that most specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region type 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to ama seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is probably at least 95 % identical to seq id no : 80 ; d ) a simple light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity element determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the identified antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id ip no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds before hpcsk9, comprising : a ) within a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid substrate sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to to seq id no : 78 ; c ) a brief heavy chain complementarity determining region mark 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining harvesting region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain specific complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope fragment comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - ligand binding fragment of an antibody that specifically binds hpcsk9, comprising : an a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining area region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) typically comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region type 1 ( lcdr1 ) comprising an amino acid sequence that is itself at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) typically comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody itself or antigen - binding dna fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acids acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region sheet 3 ( hcdr3 ) comprising an amino acid sequence that is commonly at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity carrier determining region 1 ( lcdr1 ) comprising an independent amino acid sequence that is generally at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and lastly f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - gel binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding peptide fragment 242 of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific bind to HPCSK9 include: a) Heavy chain complementary determination region 1 (HCDR1), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 76; b) heavy chain complementary determination regions2 (HCDR2), which comprises an amino acid label sequence having the same at least 95% of SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is associated with SEQ ID NO: 80At least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) identified light chain complementarity including the amino acid sequence,It comprises at least 95% of the same amino acid sequence as the SEQ ID NO: 86; f) a light chain complementary determination region 3 (LCDR3) comprising an amino acid sequence, each amino acid sequence is the same amino acid sequence as SEQ ID NO: 88.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody group binds to an epitope comprising the amino acid residue ID 238 comprising HPCSK9 (SEQ ID NO: 2 755).","238, 755"
"Only the antibody or antigen binding fragment of HPCSK9 is specifically binds, including: a) Heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3), which contains at least 95% and SEQ ID NO: 80The amino acid sequence; D) In the light chain complementary determination region 1 (LCDR1), the region 1 (LCDR1) comprises an amino acid sequence, which is at least 95% of SEQ ID NO: 84; E) a light chain complementaryDetermination of region 2 (LCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (especially LCDR3), including SEQ ABD ID NO: 88The same amino amino-amino acid sequence. 2.2. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment, its antibody binds to an epitope of an amino amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) heavy chain complementarity determined in region 1 (HCDR1), the amino acid sequence and SEQ ID NO: 76, the same amino acid sequence is at least 95%(B) a heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, which may be identified by the SEQ ID NO: 78; C) Similar heavy chain complementary determination regions 3 (HCDR3),It comprises an amino acid sequence having at least 95% of SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84;e) Light chain complementarity in region 2 (LCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) Light chain complementary determination region 3 (LCDR3), which only contains SEQID NO: 88 The same amino acid sequence is the same. 2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antibody specifically binding to HPCSK9, including: a) Heavy chain complementary identification determination region 1 (HCDR1), which comprises at least 95%, the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence that is the same as at least 95% of SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3), which comprises the entire amino acid sequence sequence, with SEQ ID NO: 80The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) a light chain neutral complementary determination region 2(LCDR2), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 21 86; f) a light chain complementary determination region region 3 (LCDR3), which comprises at least 95% to SEQ ID NO: 88 amino acid sequences.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or other antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid extract sequence, which is the same as at least 95% of SEQ ID NO: 76; b) Amino.Chain Complementary Determination Region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ Identity ID NO: 78; C) The potential heavy chain complementary determination region 3 (HCDR3) contains an amino acid sequence, which is associated with SEQThe identical NO: 80 is the same at least 95%; D) comprises a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary determination sequenceRegion 2 (LCDR2) contains an amino acid sequence sequence, which is the same as at least 95% of SEQ ID NO: 86; f) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO: 88The same amino acid sequence.The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment of the antibody group binds to an epitope of an amino group and an acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ IX ID NO: 76; b) contains amino acid sequences.The heavy chain secondary complementary determination region 2 (HCDR2), which is at least 95% substantially the same SEQ ID NO: 78; C) A heavy chain complementary determination region 3 (HCDR3) comprising at least 95% amino acid sequence, alsoThat is the same as SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising identifiable amino acid sequence, which is the same as 95% of SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence having at least 95% of the same at least 95%; F) a light chain complementary determination region 3 (LCDR3) containing at least 95% and SEQ IDs.NO: 88 The same amino acid sequence.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID token NO: 755).","238, 755"
"Specific binding of HPCSK9 antibodies or antigen binding data fragments, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising the amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) a different weightChain complementary determination determination region 2 (HCDR2) contains at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3), which comprises an amino acid sequence, with SEQID NO: 80 is at least 95% of the same; therefore d) Light chain complementary determination region 1 (LCDR1), which comprises at least 95% of the same amino acid sequence as SEQ ID IP NO: 84; E) a light chain complementary determination region2 (LCDR2) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) comprising at least 95%, the same amino acid as SEQ ID NO: 86 88.Sequence. 2.The antibody entry or antigen binding sample fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-specific binding specific binding HPCSK9 antibody fragment, including: a) heavy single-strand complementary determination region 1 (HCDR1), which comprises amino acid residue sequence, the same amino acid residue sequence as SEQ ID NO: 76; b) Heavy chain complementary determination region 2 (HCDR2), therefore comprises at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (HCDR3), which is mainly an antibody amino acid sequence,It is at least 95% of SEQ ID A ID NO: 10 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) lightChain complementary determination region 2 (LCDR2), which is mainly amino acid sequence, which is the same as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% and SEQ ID NO: 88 The same amino acid sequence.2. An antibody or antigen binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID IR NO: 755).","238, 755"
"Antibody or other antigen binding fragment specifically binding to HPCSK9, including: a) Heavy chain complementary position determines that the gene area 1 (close to HCDR1) comprising at least 95% of the same amino acid sequence as the SEQ ID: 76; b)Chain Complementary Determination Region 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (e.g., HCDR3) comprising an amino acid peptide sequence, which is associated with SEQ IDThe same at least 95% of NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination area2 (LCDR2), which contains at least 95% of the SEQ ID NO: 86; F) a light chain complementary determination region 3 (type LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid sequence.The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment of the same antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Sometimes antibodies or antigen binding fragments of antibodies that are specific bind to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence that is the same as at least 95% of SEQ ID NO: 78; C) A heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is usually with SEQ Shy ID NO: 80 The same at least 95%; D) wherein the light chain complementary determination region 1 (LCDR1) comprises at least 95%, the same amino acid sequence as SEQ ID NO: 84; E) a light chain region complementary determination region 2 (LCDR2It comprises at least 95% of the same amino or acid sequence; f) a light chain center complementary determination region 3 (LCDR3) comprising at least 95%, the same amino acid sequence as SEQ ID NO: 88..Alternatively, the antibody or antibody of the antibody or antibody according to claim 1 is the same, wherein the primary antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 85 755).","238, 755"
"The antibody component or antigen binding fragment of the antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) heavy chainComplementary determination region 2 (HCDR2), which comprises the same amino acid sequence as SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is the same as SEQ ID NO: 80At least 95%; then d) contains a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is again the same to SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2), containing amino acidsSequence, which is the same as at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) comprising an amino acid sequence itself, which is usually at least 95%, which is the same as SEQ ID NO: 88. 2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen binding fragment of antibody specific binds to HPCSK9, including: a) Heavy chain complementary determination region 1 (HCDR1) comprising an initial amino acid sequence, which is based on SEQ ID RESERVION NO: 76; B) heavy chain complementary determination region 2(HCDR2), which comprises an amino acid sequence having the same at least 95%; C) of the SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (HCDR3) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 80;d) Light Chain Complementary Determination Region 1 (LCDR1) and contains an amino acid sequence, which is about 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2) containing an amino acid sequence,At least 95%; F) of SEQ ID NO: 86; F) The light chain complementary determination region 3 (LCDR3) of the amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 88. 2.An antibody or other antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody combines an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments specific to HPCSK9 antibodies, including: a) containing heavy chain complementary determining regions 1 (HCDR1), the heavy chain complementary determination region 1 (HCDR1) contains at least 95% and SEQ ID NO : 76 The same amino acid sequence; b) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, which may be at least 95% of HIV SEQ ID NO: 78; C) a heavy chain complementary determination region 3 ( HCDR3) comprises a single amino acid sequence, which may be at least 95% of SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) containing an amino acid sequence, which is the same as SEQ ID NO: 84 At least 95%; E) a light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 86; F) determines the light chain complement of regional region 3 (LCDR3). Sex, the area region 3 (LCDR3) comprises the same amino acid sequence as SEQ ID NO: 88. 12 .12. The antibody or antigen binding protein fragment of claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Specific binding to HPCSK9 antibody or antigen binding identification fragment, including: a) a heavy chain complementary determination region 1 (represented by HCDR1) containing the amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence, which is almost the same amino acid sequence as SEQ ID NO: 78; C) has a heavy chain complementary determination region 3 (HCDR3), which contains the same as SEQ ID NO: 80.Amino acid sequence; D) A unique light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2)It includes at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 86; F) a light chain complementary determining region 3 (LCDR3) comprising at least the same amino acid sequence as SEQ ID NO: 88, at least95%, the antibody or antibody binding fragment of claim 1, wherein in which the antibody or antigen binding fragment therein, the antibody binds to the epitope of the amino acid residue 238 containing HPCSK9 (SEQ ID NO: 755).","238, 755"
"The independent antibody or antigen binding fragment of industrial antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95%: 76; b) of SEQ ID NO.Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ IDNO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, at least 95% of SEQ ID NO: 84; E) a light chain complementary determinationRegion 2 (LCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 88At least 95% .2.A particular antibody or antigen-binding fragment of the antibody according to claim 1, wherein the antigen binding fragment of the antibody or antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment specifically intensively binds to the HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising the primary sequence of the amino acid primary sequence, which is the same as that of SEQ ID NO: 57: 57 76; B) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ IDThe same at least 95% of NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination area2 (LCDR2), which comprises an amino acid sequence having the same amino acid sequence as the SEQ ID NO: 86; F) determined light chain complementary determination region 3 (LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid secondary sequence. 2.The antibody or antibody binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"An antibody or antigen binding fragment, which is specific to HPCSK9 specific binding, comprising: a) heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% as SEQ ID NO: 76;The heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID NO: 78; C) comprising a heavy chain complementary determination region 3 (HCDR3) of the amino acid sequence, which is usually with SEQID NO: 80 is at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determinationRegion 2 (LCDR2), which comprises at least 95% of the same amino acid sequence relative to SEQ ID NO: 86; F) Light chain independent complementary determination region 3 (LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid sequence. 2.The antibody or antigen binding fragment of the antibody or antibody according to claim 1, wherein the antibody or antigen binding protein fragment of the antibody binds to HPCSK9 (SEQ ID NO: 755) comprising an epitope â‰¥ 238 comprising an amino acid residue (SEQ ID NO: 755).","238, 755"
"Antibody or antigen binding fragment of antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) itselfThe heavy chain complementary determination region 2 (HCDR2) is again contained in the amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprises an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) Light chain complementary determination region 1 (LCDR1) again contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2)It comprises an amino acid sequence having the same at least 95% of the SEQ ID NO: 86; F) The light short chain complementary determination region 3 (LCDR3) further comprises at least 95% of the same amino acid sequence as SEQ ID NO: 5188.2. An antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID IdiTi: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) form a single heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% as SEQ ID NO: 76; to B)Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQID NO: 80 is at least 95%; D) a light chain complementary determination region 1 (LCDR1) which may contain amino acid sequences, the amino acid sequence is the same as at least 95% of SEQ ID NO: 84; additional E) a lightChain Complementary Determination Region 2 (LCDR2) contains an amino acid sequence, which is the same amino acid sequence as measured SEQ ID NO: 86; F) Light Chain Complementary Determination Region 3 (LCDR3), which contains at least 95% and SEQ ID NO:88 The same amino protein sequence. 2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments specific binding to HPCSK9, including: a) a heavy chain complementary coupling determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% as SEQ ID NO: 76;The heavy chain complementary determination region 2 (HCDR2) comprising a protruding amino acid sequence having the same at least 95%; C) of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (usually HCDR3), which contains amino acid sequenceIt is at least 95% of SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is identical to SEQ ID NO: 84, the same 95%; e) oneLight chain complementary determination region 2 (LCDR2) contains at least 95% of the extension of the amino acid sequence, which is the same as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95%.The same amino acid binding sequence as SEQ ID NO: 88.And the antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) Chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) a lightweight chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, and its amino acid sequence is at least 95%. The same SEQ ID and NO: 80; D) Light Chain Complementary Determination Region 1 (LCDR1) comprising an additional amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) a light chain complementary ion The measurement region 2 (LCDR2) contains an amino acid sequence, which is at least 95% of SEQ ID NO: 86; F) light single-strand complementary determination region 3 (LCDR3), which comprises an amino acid sequence, which is associated with SEQ ID NO: 88 The same amino acid sequence. 2. Antibodies, antibodies, composed of the antibody or antigen binding target fragment, as shown in Fig. 1, wherein the antibody or antigen binding fragment of the antibody binds to the epitope 238 of the amino acid residue 238 of HPCSK9, the epitope 238 of the amino acid residue 238 of HPCSK9.","238, 755"
"Antibodies or antibody antigen binding fragments consisting of antibodies specific binding HPCSK9, the antibody comprising: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, the amino acid sequence is the same amino acid as SEQ ID NO: 76. Sequence; b) Heavy chain complementary determination region 2 (HCDR2) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 78; C) combined heavy chain complementary determination region 3 (HCDR3) containing amino acid sequences, It is at least 95% of the SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) one Light chain complementary identification determination region 2 (LCDR2) contains an amino acid sequence, which is usually at least 95%; F) a light chain complementary determination region 3 (LCDR3), which contains amino acid sequences. The same is the same as at least 95% of SEQ ID NO: 88. Figure 2. A antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid sequence residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain complementary determination region 2 (HCDR2) contains an amino acid sequence which is the same as at least 95% of SEQ ID NO: 78; C) Natural Heavy Chain Complementary Determination Region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region region 1 (LCDR1) containing an amino acid sequence, which is the same as at least 95% of SEQ, Id NO: 84; E) a light chain complementDetermination of region 2 (LCDR2) contains an amino acid sequence, which is substantially at least 95%, which is the same as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% and its SEQ ID NO: 88The same amino acid sequence. 2.The antibody or antigen binding fragment of the antibody is comprised of claim 1, wherein the antibody or antigen binding fragment 117 of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Only antibodies or specific antigen binding fragments of antibodies specifically binding to HPCSK9 include: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, the amino acid sequence is the same as SEQ III ID NO: 76 95%; b) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing amino acids The sequence is at least 95% of SEQ ID NO: 80; D) a light chain complementary bearing determination region 1 (LCDR1) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 84; E) one Light chain complementary determination region 2 (LCDR2), which is included in the amino acid sequence in the same amino acid sequence as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) containing an amino acid sequence, at least 95 % Is the same as SEQ ID NO: 88.2. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen-carrier binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ IV ID NO: 755).","238, 755"
"The antibody or antigen-binding fragment of HPCSK9, including: a) Heavy double strand complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2), which comprises an amino acid sequence sequence, which is the same as at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (common HCDR3), which comprises an amino acid sequence, which is associated with SEQ ID NO:80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same as SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2), which comprises an amino acid sequence sequence, which is the same as at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which comprises at least 95%, the same amino acid as SEQ ID NO: 88.sequence.The antibody recognition or antigen-binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the target antibody binds to an epitope comprising an amino acid residue 238 bonded to HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific bind to HPCSK9 include: a) heavy chain complementary determination region region 1 (HCDR1), which contains only at least 95% of the same amino acid sequence as SEQ ID NO: 76; or B) heavy chainProtein complementarity determination region 2 (HCDR2) comprising an amino acid sequence having the same 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQID NO: 80 is at least 95%; and D) a light chain antibody complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO:88 The same amino acid sequence.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope sequence (SEQ ID NO: 755) comprising the amino acid residue 238 of HPCSK9.","238, 755"
"The antibody or antigen-binding fragment of the HPCSK9 is specifically binding to the HPCSK9 comprising: a) a heavy chain complementary determination region 1 (HCDR1) comprising the amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ Identity ID NO: 78; C) a heavy chain complementary authentication determination region 3 (HCDR3), which contains at least 95% identical to SEQ ID NO: 80.Amino acid sequence; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2),The same amino acid peptide sequence of at least 95% is identified with the manufacturer SEQ identification; f) a light chain complementary determination region 3 (LCDR3) comprising at least about 95% of the same amino acid sequence as SEQ ID NO: 88.2.The antibody or antigen binding fragment of claim 1 contains an antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody is bonded by epitope comprising the amino acid residue 238 of HPCSK9 (SEQ ID NO: 86 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having at least 95% of SEQ ID NO: 78; C) A heteric base chain complementary determination region position 3 (HCDR3), which contains at least 95% and SEQ ID NO: 80 The same amino acid sequence; D) a light chain complementary determination region 1 (LCDR1) comprising at least 95% of the same amino organic acid sequence as SEQ ID NO: 84; E) a light chain complementary determination Region 2 (LCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 80 86; F) The second light chain complementary determination region 3 (LCDR3) contains an amino acid recognition sequence, which may be with SEQ ID. NO: 87 88 Almost the same amino acid recognition sequence. 2. The antibody or antibody of the antibody or antibody is almost the same. The antibody or antigen binding fragment of the antibody is combined with an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Specific binding of antibodies or antibodies of HPCSK9 or antibodies, or including: a) or, a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, a separate amino acid sequence is the same amino acid sequence as SEQ ID NO: 76 The heavy chain complementary determination region 2 (HCDR2) containing the amino acid sequence, which is at least 95% of SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3), which contains at least 95 % Is the same amino acid sequence as SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain Complementary determination region 2 (LCDR2) contains an amino acid sequence, which is the same as at least 95%; and F) or F) or light chain complementary determination region 3 (LCDR3) as SEQ ID NO: 86, which comprises an amino acid composition sequence, which is associated with SEQ ID NO: 87 88 The same at least 95% is the same. 2. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the primary antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen binding fragment specifically binding to HPCSK9, comprising: a) heavy chain complementary determining region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain complementary determination region 2 (or HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID H NO: 78; c) a heavy chain complementary pair of accuracy zone 3 (HCDR3), including amino acid sequences,It is at least 95% of the SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1 represented by), which comprises an amino acid sequence, which is the same as at least about 95% as SEQ ID S NO: 84; EA light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence having the same at least 95%; 2 and f in which SEQ ID NO: 86; 2 and f) a light chain complementary determination region 3 (LCDR3), which containsAt least 95% of the same amino acid sequence as SEQ ID NO: 88.The antibody or antigen binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody is bonded to the epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ IDNO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) contains at least 95% almost the same amino acid chain sequence, almost the same as SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence which is itself at least 95% almost the same as SEQ ID NO: 86; and f) a light chain complementary determination region 3 (LCDR3), which comprises an amino acid segment, whichOnly 95% of SEQ ID NO: 88 is the same. 2.The antibody or antigen binding fragment of the antibody according to claim 1 includes epitope of the antibody case antibody or antigen binding fragment comprises an epitope 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific bind to HPCSK9 include: a) a heavy chain complementary determination region 1 (abbreviation HCDR1) comprising an amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) a heavy chain Complementary determination region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 96 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as SEQ et ID NO: 84; e) a light chain complement Determining region 2 (LCDR2) contains at least 95% of the same amino acid sequence as SEQ ID NO: 86; F) a light chain complementary tag determines the end region 3 (LCDR3), which contains SEQ ID RD NO: 94 88 The same amino acid sequence is at least 95% of the same: 94 88. The antibody or antigen binding fragment of the claim antibody is shown in Fig. 1, wherein the antibody or antigen binding fragment of the antibody comprises an amino acid residual comprising HPCSK9 (SEQ ID NO: 755). The epitope of the base 238.","238, 755"
"Antibodies or antigen binding fragments of antibodies specifically bind to HPCSK9 include: a) heavy chain complementary determination region 1 (HCDR1), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 76; b) comprising an amino magnetically acidic acidThe heavy chain complementary analysis of the sequence determines the region group 2 (HCDR2) having the same 95% identical to SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3), which comprises an amino acid sequence, which is associated with SEQ IDNO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino tape electric acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementDetermination of region 2 (LCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO: 88The same amino acid sequence. 2.The second antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) Heavy chain complementary determination region 1 (HCDR1) contains only an intermediate amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) comprising an amino acid sequenceThe heavy chain intermediate complementary determination region 2 (HCDR2), which is the same amino acid sequence as SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3), which comprises the same amino acid sequence as SEQ ID NO: 80.It is not at least 95%; D) A light daisy chain complementary determination region 1 (LCDR1) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2It comprises at least 95% of the same amino acid sequence as SEQ ID NO: 86; f) a light chain complementary determination region group 3 (LCDR3) comprising at least 95%, the same amino acid sequence as SEQ ID NO: 84 88.2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 of HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding signal fragment specifically binding to HPCSK9, the antibody comprises: a) comprising a heavy chain complementary determination region 1 (HCDR1), the heavy chain complementary determination region 1 (HCDR1) comprises an amino acid sequence, the amino acid The sequence is at least 95%: 76; b) Heavy chain complementary determination region 2 (HCDR2), which contains an amino acid sequence, at least 95% of SEQ ID NO: 78; C). A heavy chain complementary determination region 3 (HCDR3) comprising a complete amino acid sequence having the same at least 95% of SEQ ID NO: 80; D) Light Chain Complementary Determination Region 1 (LCDR1), which comprises an amino acid sequence, which At least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 86; f) a light chain Complementary determination region 3 (LCDR3) contains at least 95% of the same amino acid sequence as SEQ ID NO: 88. The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (as SEQ ID NO: 755).","238, 755"
"Specific binding of the antibody diagnosis or antigen-substrate binding fragment of HPCSK9, which specifically binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95 of SEQ ID NO: 76.%; B) has a heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same 95% identical to SEQ ID NO: 78; C) contains heavy chain complementary determination regions 3 (HCDR3), including amino acidsSequence, which is exactly the same amino acid sequence as SEQ ID NO: 80.D) A light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2), which comprises an amino acid sequenceIt is at least 95% of SEQ ID NO: 86; F) A light chain complementary determination region 3 (LCDR3) comprising any of the same amino acid sequences as SEQ ID NO: 88. 2. Claim 1The antibody of the antibody or antigen binding fragment, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) heavy chain complementary determination region 1 (HCDR1), which contains the same amino acid sequence as SEQ ID NO: 76 and is not the same 95%; b) one heavyChain Complementary Determination Region 2 (HCDR2) contains an amino acid substitution sequence having the same at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing abdominal amino acid sequences, whichSEQ ID NO: 6 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) containing an amino acid sequence expansion, which is the same as at least 95% of SEQ ID NO: 84; E) in structureThe light chain complementary determination region 2 (LCDR2) comprises an amino acid sequence having the same at least 95%; F) Light chain complementary determination region 3 (LCDR3) as the SEQ ID NO: 86, which comprises a substantially amino acid sequence with SEQ ID NO: 88 The same at least 95% is the same. 2.The antibody or antigen binding fragment of the antibody according to claim 1 contains an epitope of the antibody or antigen binding fragment of the antibody comprises an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"An antibody or antigen binding fragment comprising an antibody or antibody, which specifically binds to HPCSK9, including: a) heavy chain complementary determination region 1 (HCDR1), which comprises an amino acid sequence unit, at least 95% of the same similar to SEQ ID NO : 76; add B) Similar heavy chain complementary determination regions 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 78; c) a heavy chain complementary tag determination region 3 (HCDR3) It comprises at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as SEQ ID NO: 84 at least 95%. (e) a light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence having at least 95%; F), at least 95%; f) a light chain complementary determination region 3 (LCDR3), The same amino acid sequence containing at least 95% is the same as SEQ ID NO: 80 88. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specific binds to HPCSK9, including: a) heavy chain complementary determination region 1 (HCDR1), which comprises at least 95%, the same amino acid sequence as SEQ ID NO: 76; b) The corresponding heavy chain complementDetermining region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; AC), a heavy chain complementary determination region 3 (HCDR3), contains at least 95% and SEQ ID NO: 480 The same basic amino acid sequence; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2), which contains at least 95% of the same amino acid DNA sequence; F) a light chain complementary determination region 3 (LCDR3) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 88.2. Antibody or antigen binding fragment of the antibody according to claim 1, wherein the antigen binding fragment of the antibody itself or antibody binds to epitopes repeating, the epitope repeats the amino acid sequence residue 238 containing HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specifically bind to HPCSK9 include: a) Heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ IC ID NO: 76; b) heavy chainComplementary determination region 2 (HCDR2) contains at least 95% or the same amino acid sequence as SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2(LCDR2), which comprises at least 95% of the same active amino acid sequence; and 5 F) optical cross chain complementary determination region 3 (LCDR3), which comprises an amino acid sequence, which is the same as SEQ ID NO: 88.Amino acid sequence.Name 2. The antibody or antigen binding fragment of the antibody according to claim 1 includes an epitope in which a third antibody or antigen binding fragment 218 comprising HPCSK9 is combined with an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen-binding fragments that specifically bind to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is at least 95% of SEQ ID NO: 76; b) Heavy chainComplementary determination region 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3), which comprises an amino acid sequence, which is with existing SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising at least 95% identical amino acid sequence, i.e., SEQ ID NO: 84; E), in addition, a light chain containing a separate amino acid sequenceComplementary determination region 2 (LCDR2), which is the same as at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) comprising at least 95%, the same amino acid sequence as SEQ ID NO: 88..2.The claim 1 of the antibody or antigen binding fragment, wherein the antibody drug or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain Complementary Determination Region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (standard HCDR3) containing an amino acid sequence, at least 95% The same SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) Novel chain complementary analysis determined region2 (LCDR2) Further, its overall amino acid sequence, which is the same as at least 95%; 8 and f) of SEQ ID NO: 86; 8 and f) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO:88 The same amino acid sequence. 2.The antibody or antigen binding fragment residue of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 of HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or specific antigen binding fragment of the antibody of HPCSK9 was identified, including: or a) Heavy chain antigen complementarity determination region 1 (HCDR1), which comprises an amino acid sequence, which is the same as at least 95% as SEQ ID NO: 76 The heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, It is at least 95% of the SEQ IV ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) one The light chain complementary determination region 2 (LCDR2) contains an amino acid sequence having the same specificity of at least 95%, and the complement SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% The same amino acid sequence as SEQ ID NO: 88.12. The antibody or antigen binding fragment of claim 1 wherein the antibody or antigen-specific binding fragment of the antibody comprises an epitope comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; also c) a basic heavy chain chain complementary determination region 3 (HCDR3), which comprises an amino acid sequence, At least 95% of SEQ ID NO: 80; D) a light chain complementary horizontal determination region 1 (LCDR1) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 84; E) In addition, simple light Chain Chain Complementary Determination Region 2 (LCDR2) contains an external amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which comprises an amino acid sequence, each of which Amino acid sequence is 95% of SEQ ID NO: 88. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"For antibodies or antigen binding fragments specific binding HPCSK9, including: a) Heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) comprising amino acid sequencesHeavy chain complementary determination region 2 (HCDR2), which is the same amino acid sequence as SEQ ID NO: 78; plus C) heavy chain complementary determination region 3 (HCDR3), which comprises an amino acid sequence, which is the same as at least 95% of SEQ ID NO.D) A light chain complementary determination region 1 (LCDR1) comprising an amino acid recognition sequence, which is the same as at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2), which containsAmino acid identification sequence, which is the same as at least 95% of SEQ ID NO: 86; Figures 6 and f) 6 and f) a light chain complementary determination region 3 (LCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 88At least 95% .2.The antibody or antigen binding fragment comprises the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen-binding fragment specifically binding to HPCSK9, generally comprising: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) heavy chain complementary determination regions2 (SR HCDR2), which comprises at least 95% of the amino acid sequence, the amino acid sequence is the same as SEQ Sr ID NO: 78; B C) Heavy chain complementary determination region 3 (HCDR3), which comprises a amino acid sequence sequence, at least with SEQ IDNO: 80 is the same 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ SD ID NO: 84; E) a light chain complementary region2 (LCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) Light chain complementary determination region 3 (LCDR3), which comprises at least 95%, the same amino acid as SEQ ID NO: 85 88.Sequence. 2.The antibody or antigen binding fragment of the antibody or antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen-binding fragment of HPCSK9 is most specific, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising at least 95% of the same amino acid sequence as AMA SEQ ID NO: 76; b) Heavy chain complementDetermination of region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which may be with SEQ ID NO: 80 The same at least 95%; D) A simple light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary elementDetermining region 2 (LCDR2) contains at least 95% of the same amino acid sequence as the SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid sequence.The antibody or antigen-binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the identified antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID IP NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies, which specifically binds to HPCSK9, including: a), in the heavy chain complementary determination region 1 (HCDR1), the heavy chain complementary region 1 (HCDR1) comprises an amino acid substrate sequence, The amino acid substrate sequence as the amino acid substrate sequence is the same as the SEQ ID NO: 76; B) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, at least 95% Same SEQ ID NO: 78; C) A short heavy chain complementary determination region indicia 3 (HCDR3) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 80; D) A light chain complementary determination harvest region 1 (LCDR1), which contains amino acids The sequence is at least 95% of SEQ ID NO: 84; e) a light chain-specific complementary determination region 2 (LCDR2) comprising an amino acid sequence having the same at least 95% as SEQ ID NO: 86; F A light chain complementary determination region 3 (LCDR3) comprising an amino acid sequence having at least 95% of SEQ ID NO: 88. 2. Antibody or antigen binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope fragment comprising the amino acid residue 238 of HPCSK9 (SEQ ID NO: 755).","238, 755"
"Specific binding to HPCSK9 antibodies or antigen-ligand binders, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% as SEQ ID NO: 76; b)Heavy chain complementary determination region 2 (HCDR2) contains an amino acid sequence which is the same as at least 95% of SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3) typically comprises an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) Light chain complementary determination region 2 (LCDR2) typically comprises at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) having a light chain complementary determination region 3 (LCDR3), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 88.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody itself or antibody antigen binding DNA fragment combines an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising a amino acid sequence, at least 95% of SEQ ID NO: 76; b) heavy chain complementary determinationRegion 2 (HCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region piece 3 (HCDR3) containing an amino acid sequence, which is usually with SEQ ID NO: 80 The same at least 95%; D) a light chain mutual feedstock determination region 1 (LCDR1) containing at least 95% of the same independent amino acid sequence as SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence which is the same as at least 95% of SEQ ID NO: 86; and is F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% and SEQ ID.NO: 88 The same amino acid sequence. 2.The antibody or antigen-gel binding fragment of the antibody according to claim 1, wherein the antibody of the antibody or antigen binding peptide fragment 242 binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising altogether an amino acid sequence that is at least 95 % identical to an seq id no : 76 ; b ) a heavy chain complementarity determining region region 2 ( hcdr2 ) comprising an amino acid tag sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity identifying determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that each is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody group binds an epitope comprising amino acid residue id 238 of hpcsk9 ( seq id id no : 2 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that only specifically binds hpcsk9, comprising : an a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least of 95 % identical to seq id no : 80 ; d ) within a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least to 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( specifically lcdr3 ) comprising an amino aromatic acid sequence that is at least 95 % identical to seq abd id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of which the antibody binds an epitope comprising amino amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an artificial antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining in region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that likely is at least 95 % identical to seq id identification no : 78 ; c ) a similar heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining within region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising only an amino acid sequence that is at any least 95 % identical to the seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising the amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of or an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity identification determining region 1 ( hcdr1 ) comprising an all amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an entire amino acid sequences sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain neutral complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 21 86 ; and f ) a light chain complementarity determining region region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical overall to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or other antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid extract sequence sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy amino chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq identity id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) potentially comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) comprising a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining sequence region 2 ( lcdr2 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody group binds an epitope comprising amino and acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq ix id no : 76 ; b ) a heavy chain secondary complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % basically identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % also identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an identifiable amino acid sequence that is at least 95 % identical identical to seq id id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least nearly 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical as to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id token no : 755 ).","238, 755"
"an antibody or antigen - binding data fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a distinct heavy chain complementarity determining determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; thus d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % fully identical to seq id ip no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical as to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 88. 2. the antibody entry or antigen - binding sample fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - specifically binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy single chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid residues sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) thus comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising principally an antibody amino acid sequence that is at least 95 % identical to seq ida id no : 10 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising predominantly an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id ir no : 755 ).","238, 755"
"an antibody or other antigen - binding fragment of an antibody form that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity position determining gene region 1 ( near hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( like hcdr3 ) comprising an amino acid peptide sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical relative to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( type lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the same antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that sometimes specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is usually at least 95 % identical to seq shy id no : 80 ; d ) wherein a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain regional complementarity determining region 2 ( lcdr2 ) comprising an amino or acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain central complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. alternatively the antibody or antigen - binding fragment of an antibody of claim 1, wherein the primary antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 85 755 ).","238, 755"
"an antibody component or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region zone 2 ( hcdr2 ) comprising an amino acid sequence that previously is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; then d ) contain a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at to least 95 % identical again to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence itself that is typically at least 95 % identical to seq id no : 88. 2. involve the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an initial amino acid sequence that is at least 95 % identical according to seq id accession no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising upon an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) and comprising an amino acid sequence that is approximately at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or other antigen - binding fragment composed of an antibody of claim 1, wherein both the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) containing a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is probably at least 95 % identical to hiv seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an individual amino acid sequence that likely is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining regional region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. plot 2. the antibody or antigen - binding protein fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue type 238 of an hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding identification fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( denoted hcdr1 ) comprising an amino acid sequence that is at which least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % virtually identical to seq id no : 78 ; c ) possessing a heavy chain complementarity determining region 3 ( hcdr3 ) comprising altogether an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a unique light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least to 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein wherein the antibody or antigen - binding fragment of whereby the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an independent antibody or antigen - binding fragment of an industrial antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid acid sequences sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least exactly 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that that is at least 95 % identical to seq id no : 88. 2. observe the special antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or a antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of the hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically strongly binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid primary sequence that is at any least 95 % identical to seq id no : 57 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % as identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is broadly at least 95 % identical with to his seq id no : 86 ; and f ) a determined light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid secondary sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of type an antibody that specifically binds with hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that generally is at least least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical relative to seq id no : 86 ; and f ) a light chain independent complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, and wherein the antibody or antigen - binding protein fragment of the antibody binds an epitope comprising amino acid residue â„– 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) itself a heavy chain complementarity determining region 2 ( hcdr2 ) again comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising comprises an amino acid sequence that is at least least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) again comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id identification no : 86 ; and f ) a light short chain complementarity determining region 3 ( lcdr3 ) also comprising an amino acid sequence that is at least 95 % identical to seq id no : 51 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id identity no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) forming a single heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; to b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is also at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) possibly comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; also e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to measured seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino protein acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of the claim 1, formed wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity coupling determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising prominently an incorporated amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( usually hcdr3 ) comprising an amino acid sequence that is at least as 95 % identical to seq id id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical exactly to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an extended amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid binding sequence that is at least 95 % identical to seq id no : 88. and 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a light heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % structurally identical to seq id and no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising additionally an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity ion determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light single chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding target fragment compose of an antibody of claim division 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 representative of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antibody antigen - binding fragment composed of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) as comprising an amino acid sequence that is at least 95 % equally identical to seq id no : 78 ; c ) a combined heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical identical to seq id no : 84 ; e ) a light chain complementarity identification determining region 2 ( lcdr2 ) comprising an amino acid sequence that typically is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. figure 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid sequences residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy long chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a native heavy chain complementarity determining region 3 ( hcdr3 ) either comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq as id no : 84 ; e ) a light chain complementarity determining region unit 2 ( lcdr2 ) comprising an amino acid sequence that is roughly at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to its seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody consists of claim 1, wherein the antibody or antigen - binding fragment 117 of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or specific antigen - binding fragment of solely an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq iii id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to an seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity bearing determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at... least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % that identical to seq id no : 88. 2. the resulting antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - carrier binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq iv id no : 755 ).","238, 755"
"an antibody or either antigen - binding fragment of an antibody type that specifically binds hpcsk9, comprising : a ) a heavy twin chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( commonly hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least as 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody recognizes or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the target antibody binds an epitope comprising amino acid residue 238 of binding hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : an a ) a heavy chain complementarity determining region region 1 ( hcdr1 ) comprising only an amino acid sequence that is at least 95 % identical to an seq id no : 76 ; or b ) a heavy chain protein complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least to 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; and d ) a light chain antibody complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope sequence comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that of specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq identity id no : 78 ; c ) a heavy chain complementarity authentication determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid peptide sequence that is at least 95 % identical to manufacturer seq identification id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least approximately 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of containing an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds through an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 86 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy base chain complementarity determining region position 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino organic acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 86 ; and f ) a second light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid recognition sequence that that perhaps is at least 95 % almost identical to seq id no : 87 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an initial antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, or comprising : a ) alternatively a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that alone is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least again 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least another 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) or a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid composition sequence that is at least 95 % identical to seq id no : 87 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the primary antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically physically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( or hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id h no : 78 ; c ) a heavy chain complementarity alignment determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( denoted lcdr1 ) comprising an amino acid sequence that is at least approximately 95 % identical to seq id s no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is itself at least 95 % identical to seq id no : 86 ; 2 and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds on an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid chain sequence that is at least 95 % almost identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that itself is at least 95 % nearly identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acidic acid sequence segment that is at least 95 % identical solely to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, includes wherein case the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue line 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( abbreviated hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 96 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is any at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is all at least 95 % identical to seq et id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % entirely identical to seq id no : 86 ; and f ) a light chain complementarity tag determining terminal region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id rd no : 94 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is externally at least 95 % identical to its seq id no : 76 ; b ) a heavy chain complementarity analysis determining region group 2 ( hcdr2 ) comprising an amino magnetic acid sequence that itself is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino charged acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the second antibody or antigen - binding fragment of an antibody of claim number 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) only comprising an intermediate amino acid sequence that is not at least 95 % identical to seq id no : 76 ; b ) a heavy chain intermediate complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region type 3 ( hcdr3 ) comprising an amino acid sequence that is not at least 95 % identical to seq id no : 80 ; d ) a light daisy chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % itself identical to seq id no : 86 ; and f ) a light chain complementarity determining region group 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding signal fragment of an antibody that specifically binds hpcsk9, comprising : a ) containing a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence there that is at least 95 % identical to a seq id tag no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 )... comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an intact amino acid sequence himself that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region area 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( as seq id no : 755 ).","238, 755"
"an antibody diagnostic or antigen - substrate binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) features a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least exactly 95 % identical to seq id no no : 78 ; c ) contains a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % perfectly identical to seq id no : 80 ; d ) a light light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acids acid sequence that is at any least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is not at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid substitution sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an abdominal amino acid sequence that is at least 95 % identical to the seq id no : 6 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence expansion that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) structurally comprising an amino acid sequence that is at least 95 % identical to seq id id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising approximately an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, contains wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"include an antibody or antigen - binding fragment of an antibody that otherwise specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence unit that is at least nearly 95 % approximately identical to seq id no : 76 ; plus b ) a similar heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity tag determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least nearly 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id ind no : 76 ; b ) a corresponding heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; a c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an essential amino acid sequence that is at least 95 % identical to seq id no : 4 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising thereof an amino acid dna sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody itself or antigen - binding fragment of the antibody binds an epitope repeat comprising amino acid sequence residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq ic id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least exactly 95 % or identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an active amino acid sequence that is at least 95 % identical to seq id no : 86 ; and 5 f ) a light cross chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. name 2. the antibody or antigen - binding fragment of an antibody of claim 1, comprise wherein the third antibody or antigen - binding fragment 218 of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an international antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that itself is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least a 95 % identical to existing seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical simply to seq id no : 84 ; e ) furthermore a light chain complementarity determining region 2 ( lcdr2 ) comprising an independent amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. and the antibody or antigen - binding fragment of an antibody of claim genus 1, wherein the antibody drug or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( standard hcdr3 ) comprising an amino acid sequence average that is at least 95 % identical out to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light novel chain complementarity analysis determining region 2 ( lcdr2 ) additionally comprising an amino acid sequence overall that is at least 95 % identical to seq id no : 86 ; 8 and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment remains of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"identifying an antibody or specific antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : or a ) a heavy chain antigen complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq iv id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that specifically is at least 95 % identical to complement seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. map 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein precisely the antibody or antigen - specific binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; also c ) a basic heavy chain chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to the seq id no : 80 ; d ) a light chain complementarity level determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) furthermore a simple light chain chain complementarity determining region 2 ( lcdr2 ) comprising an outer amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is each at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"for an antibody or antigen - binding fragment of of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at or least 95 % identical to seq id no : 78 ; plus c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : of 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid recognition sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid identification sequence that is at at least 95 % identical to seq id no : 86 ; 6 and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment includes of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, usually comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( sr hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq sr id no : 78 ; b c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence sequence that is at least something 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq sd id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 85 88. 2. examine the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope comprising amino acid residue 238 inclusive of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of either an antibody that most specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region type 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to ama seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) comprising an amino acid sequence that is probably at least 95 % identical to seq id no : 80 ; d ) a simple light chain complementarity determining region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity element determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the identified antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id ip no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds before hpcsk9, comprising : a ) within a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid substrate sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to to seq id no : 78 ; c ) a brief heavy chain complementarity determining region mark 3 ( hcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining harvesting region 1 ( lcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 84 ; e ) a light chain specific complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding fragment of the antibody binds an epitope fragment comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - ligand binding fragment of an antibody that specifically binds hpcsk9, comprising : an a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining area region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical identical to seq id no : 78 ; c ) a heavy chain complementarity determining region 3 ( hcdr3 ) typically comprising an amino acid sequence that is at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity determining region type 1 ( lcdr1 ) comprising an amino acid sequence that is itself at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) typically comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - binding fragment of an antibody of claim 1, wherein the antibody itself or antigen - binding dna fragment of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"an antibody or antigen - binding fragment of an antibody that specifically binds hpcsk9, comprising : a ) a heavy chain complementarity determining region 1 ( hcdr1 ) comprising an amino acids acid sequence that is at least 95 % identical to seq id no : 76 ; b ) a heavy chain complementarity determining region 2 ( hcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 78 ; c ) a heavy chain complementarity determining region sheet 3 ( hcdr3 ) comprising an amino acid sequence that is commonly at least 95 % identical to seq id no : 80 ; d ) a light chain complementarity carrier determining region 1 ( lcdr1 ) comprising an independent amino acid sequence that is generally at least 95 % identical to seq id no : 84 ; e ) a light chain complementarity determining region 2 ( lcdr2 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 86 ; and lastly f ) a light chain complementarity determining region 3 ( lcdr3 ) comprising an amino acid sequence that is at least 95 % identical to seq id no : 88. 2. the antibody or antigen - gel binding fragment of an antibody of claim 1, wherein the antibody or antigen - binding peptide fragment 242 of the antibody binds an epitope comprising amino acid residue 238 of hpcsk9 ( seq id no : 755 ).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific bind to HPCSK9 include: a) Heavy chain complementary determination region 1 (HCDR1), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 76; b) heavy chain complementary determination regions2 (HCDR2), which comprises an amino acid label sequence having the same at least 95% of SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is associated with SEQ ID NO: 80At least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) identified light chain complementarity including the amino acid sequence,It comprises at least 95% of the same amino acid sequence as the SEQ ID NO: 86; f) a light chain complementary determination region 3 (LCDR3) comprising an amino acid sequence, each amino acid sequence is the same amino acid sequence as SEQ ID NO: 88.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody group binds to an epitope comprising the amino acid residue ID 238 comprising HPCSK9 (SEQ ID NO: 2 755).","238, 755"
"Only the antibody or antigen binding fragment of HPCSK9 is specifically binds, including: a) Heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3), which contains at least 95% and SEQ ID NO: 80The amino acid sequence; D) In the light chain complementary determination region 1 (LCDR1), the region 1 (LCDR1) comprises an amino acid sequence, which is at least 95% of SEQ ID NO: 84; E) a light chain complementaryDetermination of region 2 (LCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (especially LCDR3), including SEQ ABD ID NO: 88The same amino amino-amino acid sequence. 2.2. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment, its antibody binds to an epitope of an amino amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) heavy chain complementarity determined in region 1 (HCDR1), the amino acid sequence and SEQ ID NO: 76, the same amino acid sequence is at least 95%(B) a heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, which may be identified by the SEQ ID NO: 78; C) Similar heavy chain complementary determination regions 3 (HCDR3),It comprises an amino acid sequence having at least 95% of SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84;e) Light chain complementarity in region 2 (LCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) Light chain complementary determination region 3 (LCDR3), which only contains SEQID NO: 88 The same amino acid sequence is the same. 2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antibody specifically binding to HPCSK9, including: a) Heavy chain complementary identification determination region 1 (HCDR1), which comprises at least 95%, the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence that is the same as at least 95% of SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3), which comprises the entire amino acid sequence sequence, with SEQ ID NO: 80The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) a light chain neutral complementary determination region 2(LCDR2), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 21 86; f) a light chain complementary determination region region 3 (LCDR3), which comprises at least 95% to SEQ ID NO: 88 amino acid sequences.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or other antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid extract sequence, which is the same as at least 95% of SEQ ID NO: 76; b) Amino.Chain Complementary Determination Region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ Identity ID NO: 78; C) The potential heavy chain complementary determination region 3 (HCDR3) contains an amino acid sequence, which is associated with SEQThe identical NO: 80 is the same at least 95%; D) comprises a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary determination sequenceRegion 2 (LCDR2) contains an amino acid sequence sequence, which is the same as at least 95% of SEQ ID NO: 86; f) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO: 88The same amino acid sequence.The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment of the antibody group binds to an epitope of an amino group and an acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ IX ID NO: 76; b) contains amino acid sequences.The heavy chain secondary complementary determination region 2 (HCDR2), which is at least 95% substantially the same SEQ ID NO: 78; C) A heavy chain complementary determination region 3 (HCDR3) comprising at least 95% amino acid sequence, alsoThat is the same as SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising identifiable amino acid sequence, which is the same as 95% of SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence having at least 95% of the same at least 95%; F) a light chain complementary determination region 3 (LCDR3) containing at least 95% and SEQ IDs.NO: 88 The same amino acid sequence.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID token NO: 755).","238, 755"
"Specific binding of HPCSK9 antibodies or antigen binding data fragments, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising the amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) a different weightChain complementary determination determination region 2 (HCDR2) contains at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3), which comprises an amino acid sequence, with SEQID NO: 80 is at least 95% of the same; therefore d) Light chain complementary determination region 1 (LCDR1), which comprises at least 95% of the same amino acid sequence as SEQ ID IP NO: 84; E) a light chain complementary determination region2 (LCDR2) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) comprising at least 95%, the same amino acid as SEQ ID NO: 86 88.Sequence. 2.The antibody entry or antigen binding sample fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-specific binding specific binding HPCSK9 antibody fragment, including: a) heavy single-strand complementary determination region 1 (HCDR1), which comprises amino acid residue sequence, the same amino acid residue sequence as SEQ ID NO: 76; b) Heavy chain complementary determination region 2 (HCDR2), therefore comprises at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (HCDR3), which is mainly an antibody amino acid sequence,It is at least 95% of SEQ ID A ID NO: 10 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) lightChain complementary determination region 2 (LCDR2), which is mainly amino acid sequence, which is the same as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% and SEQ ID NO: 88 The same amino acid sequence.2. An antibody or antigen binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID IR NO: 755).","238, 755"
"Antibody or other antigen binding fragment specifically binding to HPCSK9, including: a) Heavy chain complementary position determines that the gene area 1 (close to HCDR1) comprising at least 95% of the same amino acid sequence as the SEQ ID: 76; b)Chain Complementary Determination Region 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (e.g., HCDR3) comprising an amino acid peptide sequence, which is associated with SEQ IDThe same at least 95% of NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination area2 (LCDR2), which contains at least 95% of the SEQ ID NO: 86; F) a light chain complementary determination region 3 (type LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid sequence.The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment of the same antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Sometimes antibodies or antigen binding fragments of antibodies that are specific bind to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence that is the same as at least 95% of SEQ ID NO: 78; C) A heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is usually with SEQ Shy ID NO: 80 The same at least 95%; D) wherein the light chain complementary determination region 1 (LCDR1) comprises at least 95%, the same amino acid sequence as SEQ ID NO: 84; E) a light chain region complementary determination region 2 (LCDR2It comprises at least 95% of the same amino or acid sequence; f) a light chain center complementary determination region 3 (LCDR3) comprising at least 95%, the same amino acid sequence as SEQ ID NO: 88..Alternatively, the antibody or antibody of the antibody or antibody according to claim 1 is the same, wherein the primary antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 85 755).","238, 755"
"The antibody component or antigen binding fragment of the antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) heavy chainComplementary determination region 2 (HCDR2), which comprises the same amino acid sequence as SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is the same as SEQ ID NO: 80At least 95%; then d) contains a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is again the same to SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2), containing amino acidsSequence, which is the same as at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) comprising an amino acid sequence itself, which is usually at least 95%, which is the same as SEQ ID NO: 88. 2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen binding fragment of antibody specific binds to HPCSK9, including: a) Heavy chain complementary determination region 1 (HCDR1) comprising an initial amino acid sequence, which is based on SEQ ID RESERVION NO: 76; B) heavy chain complementary determination region 2(HCDR2), which comprises an amino acid sequence having the same at least 95%; C) of the SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (HCDR3) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 80;d) Light Chain Complementary Determination Region 1 (LCDR1) and contains an amino acid sequence, which is about 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2) containing an amino acid sequence,At least 95%; F) of SEQ ID NO: 86; F) The light chain complementary determination region 3 (LCDR3) of the amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 88. 2.An antibody or other antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody combines an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments specific to HPCSK9 antibodies, including: a) containing heavy chain complementary determining regions 1 (HCDR1), the heavy chain complementary determination region 1 (HCDR1) contains at least 95% and SEQ ID NO : 76 The same amino acid sequence; b) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, which may be at least 95% of HIV SEQ ID NO: 78; C) a heavy chain complementary determination region 3 ( HCDR3) comprises a single amino acid sequence, which may be at least 95% of SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) containing an amino acid sequence, which is the same as SEQ ID NO: 84 At least 95%; E) a light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 86; F) determines the light chain complement of regional region 3 (LCDR3). Sex, the area region 3 (LCDR3) comprises the same amino acid sequence as SEQ ID NO: 88. 12 .12. The antibody or antigen binding protein fragment of claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Specific binding to HPCSK9 antibody or antigen binding identification fragment, including: a) a heavy chain complementary determination region 1 (represented by HCDR1) containing the amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2) contains an amino acid sequence, which is almost the same amino acid sequence as SEQ ID NO: 78; C) has a heavy chain complementary determination region 3 (HCDR3), which contains the same as SEQ ID NO: 80.Amino acid sequence; D) A unique light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2)It includes at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 86; F) a light chain complementary determining region 3 (LCDR3) comprising at least the same amino acid sequence as SEQ ID NO: 88, at least95%, the antibody or antibody binding fragment of claim 1, wherein in which the antibody or antigen binding fragment therein, the antibody binds to the epitope of the amino acid residue 238 containing HPCSK9 (SEQ ID NO: 755).","238, 755"
"The independent antibody or antigen binding fragment of industrial antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95%: 76; b) of SEQ ID NO.Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ IDNO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, at least 95% of SEQ ID NO: 84; E) a light chain complementary determinationRegion 2 (LCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 88At least 95% .2.A particular antibody or antigen-binding fragment of the antibody according to claim 1, wherein the antigen binding fragment of the antibody or antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment specifically intensively binds to the HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising the primary sequence of the amino acid primary sequence, which is the same as that of SEQ ID NO: 57: 57 76; B) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ IDThe same at least 95% of NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination area2 (LCDR2), which comprises an amino acid sequence having the same amino acid sequence as the SEQ ID NO: 86; F) determined light chain complementary determination region 3 (LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid secondary sequence. 2.The antibody or antibody binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"An antibody or antigen binding fragment, which is specific to HPCSK9 specific binding, comprising: a) heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% as SEQ ID NO: 76;The heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID NO: 78; C) comprising a heavy chain complementary determination region 3 (HCDR3) of the amino acid sequence, which is usually with SEQID NO: 80 is at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determinationRegion 2 (LCDR2), which comprises at least 95% of the same amino acid sequence relative to SEQ ID NO: 86; F) Light chain independent complementary determination region 3 (LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid sequence. 2.The antibody or antigen binding fragment of the antibody or antibody according to claim 1, wherein the antibody or antigen binding protein fragment of the antibody binds to HPCSK9 (SEQ ID NO: 755) comprising an epitope â‰¥ 238 comprising an amino acid residue (SEQ ID NO: 755).","238, 755"
"Antibody or antigen binding fragment of antibody specific binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) itselfThe heavy chain complementary determination region 2 (HCDR2) is again contained in the amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprises an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) Light chain complementary determination region 1 (LCDR1) again contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2)It comprises an amino acid sequence having the same at least 95% of the SEQ ID NO: 86; F) The light short chain complementary determination region 3 (LCDR3) further comprises at least 95% of the same amino acid sequence as SEQ ID NO: 5188.2. An antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID IdiTi: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) form a single heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% as SEQ ID NO: 76; to B)Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQID NO: 80 is at least 95%; D) a light chain complementary determination region 1 (LCDR1) which may contain amino acid sequences, the amino acid sequence is the same as at least 95% of SEQ ID NO: 84; additional E) a lightChain Complementary Determination Region 2 (LCDR2) contains an amino acid sequence, which is the same amino acid sequence as measured SEQ ID NO: 86; F) Light Chain Complementary Determination Region 3 (LCDR3), which contains at least 95% and SEQ ID NO:88 The same amino protein sequence. 2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments specific binding to HPCSK9, including: a) a heavy chain complementary coupling determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% as SEQ ID NO: 76;The heavy chain complementary determination region 2 (HCDR2) comprising a protruding amino acid sequence having the same at least 95%; C) of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (usually HCDR3), which contains amino acid sequenceIt is at least 95% of SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is identical to SEQ ID NO: 84, the same 95%; e) oneLight chain complementary determination region 2 (LCDR2) contains at least 95% of the extension of the amino acid sequence, which is the same as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95%.The same amino acid binding sequence as SEQ ID NO: 88.And the antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) Chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) a lightweight chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, and its amino acid sequence is at least 95%. The same SEQ ID and NO: 80; D) Light Chain Complementary Determination Region 1 (LCDR1) comprising an additional amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) a light chain complementary ion The measurement region 2 (LCDR2) contains an amino acid sequence, which is at least 95% of SEQ ID NO: 86; F) light single-strand complementary determination region 3 (LCDR3), which comprises an amino acid sequence, which is associated with SEQ ID NO: 88 The same amino acid sequence. 2. Antibodies, antibodies, composed of the antibody or antigen binding target fragment, as shown in Fig. 1, wherein the antibody or antigen binding fragment of the antibody binds to the epitope 238 of the amino acid residue 238 of HPCSK9, the epitope 238 of the amino acid residue 238 of HPCSK9.","238, 755"
"Antibodies or antibody antigen binding fragments consisting of antibodies specific binding HPCSK9, the antibody comprising: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, the amino acid sequence is the same amino acid as SEQ ID NO: 76. Sequence; b) Heavy chain complementary determination region 2 (HCDR2) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 78; C) combined heavy chain complementary determination region 3 (HCDR3) containing amino acid sequences, It is at least 95% of the SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) one Light chain complementary identification determination region 2 (LCDR2) contains an amino acid sequence, which is usually at least 95%; F) a light chain complementary determination region 3 (LCDR3), which contains amino acid sequences. The same is the same as at least 95% of SEQ ID NO: 88. Figure 2. A antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid sequence residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain complementary determination region 2 (HCDR2) contains an amino acid sequence which is the same as at least 95% of SEQ ID NO: 78; C) Natural Heavy Chain Complementary Determination Region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region region 1 (LCDR1) containing an amino acid sequence, which is the same as at least 95% of SEQ, Id NO: 84; E) a light chain complementDetermination of region 2 (LCDR2) contains an amino acid sequence, which is substantially at least 95%, which is the same as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% and its SEQ ID NO: 88The same amino acid sequence. 2.The antibody or antigen binding fragment of the antibody is comprised of claim 1, wherein the antibody or antigen binding fragment 117 of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Only antibodies or specific antigen binding fragments of antibodies specifically binding to HPCSK9 include: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, the amino acid sequence is the same as SEQ III ID NO: 76 95%; b) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing amino acids The sequence is at least 95% of SEQ ID NO: 80; D) a light chain complementary bearing determination region 1 (LCDR1) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 84; E) one Light chain complementary determination region 2 (LCDR2), which is included in the amino acid sequence in the same amino acid sequence as SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) containing an amino acid sequence, at least 95 % Is the same as SEQ ID NO: 88.2. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen-carrier binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ IV ID NO: 755).","238, 755"
"The antibody or antigen-binding fragment of HPCSK9, including: a) Heavy double strand complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) Heavy chain complementary determinationRegion 2 (HCDR2), which comprises an amino acid sequence sequence, which is the same as at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (common HCDR3), which comprises an amino acid sequence, which is associated with SEQ ID NO:80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same as SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2), which comprises an amino acid sequence sequence, which is the same as at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which comprises at least 95%, the same amino acid as SEQ ID NO: 88.sequence.The antibody recognition or antigen-binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the target antibody binds to an epitope comprising an amino acid residue 238 bonded to HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific bind to HPCSK9 include: a) heavy chain complementary determination region region 1 (HCDR1), which contains only at least 95% of the same amino acid sequence as SEQ ID NO: 76; or B) heavy chainProtein complementarity determination region 2 (HCDR2) comprising an amino acid sequence having the same 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQID NO: 80 is at least 95%; and D) a light chain antibody complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO:88 The same amino acid sequence.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope sequence (SEQ ID NO: 755) comprising the amino acid residue 238 of HPCSK9.","238, 755"
"The antibody or antigen-binding fragment of the HPCSK9 is specifically binding to the HPCSK9 comprising: a) a heavy chain complementary determination region 1 (HCDR1) comprising the amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ Identity ID NO: 78; C) a heavy chain complementary authentication determination region 3 (HCDR3), which contains at least 95% identical to SEQ ID NO: 80.Amino acid sequence; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2),The same amino acid peptide sequence of at least 95% is identified with the manufacturer SEQ identification; f) a light chain complementary determination region 3 (LCDR3) comprising at least about 95% of the same amino acid sequence as SEQ ID NO: 88.2.The antibody or antigen binding fragment of claim 1 contains an antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody is bonded by epitope comprising the amino acid residue 238 of HPCSK9 (SEQ ID NO: 86 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having at least 95% of SEQ ID NO: 78; C) A heteric base chain complementary determination region position 3 (HCDR3), which contains at least 95% and SEQ ID NO: 80 The same amino acid sequence; D) a light chain complementary determination region 1 (LCDR1) comprising at least 95% of the same amino organic acid sequence as SEQ ID NO: 84; E) a light chain complementary determination Region 2 (LCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 80 86; F) The second light chain complementary determination region 3 (LCDR3) contains an amino acid recognition sequence, which may be with SEQ ID. NO: 87 88 Almost the same amino acid recognition sequence. 2. The antibody or antibody of the antibody or antibody is almost the same. The antibody or antigen binding fragment of the antibody is combined with an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Specific binding of antibodies or antibodies of HPCSK9 or antibodies, or including: a) or, a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, a separate amino acid sequence is the same amino acid sequence as SEQ ID NO: 76 The heavy chain complementary determination region 2 (HCDR2) containing the amino acid sequence, which is at least 95% of SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3), which contains at least 95 % Is the same amino acid sequence as SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain Complementary determination region 2 (LCDR2) contains an amino acid sequence, which is the same as at least 95%; and F) or F) or light chain complementary determination region 3 (LCDR3) as SEQ ID NO: 86, which comprises an amino acid composition sequence, which is associated with SEQ ID NO: 87 88 The same at least 95% is the same. 2. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the primary antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen binding fragment specifically binding to HPCSK9, comprising: a) heavy chain complementary determining region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain complementary determination region 2 (or HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID H NO: 78; c) a heavy chain complementary pair of accuracy zone 3 (HCDR3), including amino acid sequences,It is at least 95% of the SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1 represented by), which comprises an amino acid sequence, which is the same as at least about 95% as SEQ ID S NO: 84; EA light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence having the same at least 95%; 2 and f in which SEQ ID NO: 86; 2 and f) a light chain complementary determination region 3 (LCDR3), which containsAt least 95% of the same amino acid sequence as SEQ ID NO: 88.The antibody or antigen binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody is bonded to the epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ IDNO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) contains at least 95% almost the same amino acid chain sequence, almost the same as SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence which is itself at least 95% almost the same as SEQ ID NO: 86; and f) a light chain complementary determination region 3 (LCDR3), which comprises an amino acid segment, whichOnly 95% of SEQ ID NO: 88 is the same. 2.The antibody or antigen binding fragment of the antibody according to claim 1 includes epitope of the antibody case antibody or antigen binding fragment comprises an epitope 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specific bind to HPCSK9 include: a) a heavy chain complementary determination region 1 (abbreviation HCDR1) comprising an amino acid sequence, which is the same amino acid sequence as SEQ ID NO: 76; b) a heavy chain Complementary determination region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 96 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as SEQ et ID NO: 84; e) a light chain complement Determining region 2 (LCDR2) contains at least 95% of the same amino acid sequence as SEQ ID NO: 86; F) a light chain complementary tag determines the end region 3 (LCDR3), which contains SEQ ID RD NO: 94 88 The same amino acid sequence is at least 95% of the same: 94 88. The antibody or antigen binding fragment of the claim antibody is shown in Fig. 1, wherein the antibody or antigen binding fragment of the antibody comprises an amino acid residual comprising HPCSK9 (SEQ ID NO: 755). The epitope of the base 238.","238, 755"
"Antibodies or antigen binding fragments of antibodies specifically bind to HPCSK9 include: a) heavy chain complementary determination region 1 (HCDR1), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 76; b) comprising an amino magnetically acidic acidThe heavy chain complementary analysis of the sequence determines the region group 2 (HCDR2) having the same 95% identical to SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3), which comprises an amino acid sequence, which is associated with SEQ IDNO: 80 is the same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino tape electric acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementDetermination of region 2 (LCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO: 88The same amino acid sequence. 2.The second antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) Heavy chain complementary determination region 1 (HCDR1) contains only an intermediate amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) comprising an amino acid sequenceThe heavy chain intermediate complementary determination region 2 (HCDR2), which is the same amino acid sequence as SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3), which comprises the same amino acid sequence as SEQ ID NO: 80.It is not at least 95%; D) A light daisy chain complementary determination region 1 (LCDR1) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2It comprises at least 95% of the same amino acid sequence as SEQ ID NO: 86; f) a light chain complementary determination region group 3 (LCDR3) comprising at least 95%, the same amino acid sequence as SEQ ID NO: 84 88.2.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 of HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding signal fragment specifically binding to HPCSK9, the antibody comprises: a) comprising a heavy chain complementary determination region 1 (HCDR1), the heavy chain complementary determination region 1 (HCDR1) comprises an amino acid sequence, the amino acid The sequence is at least 95%: 76; b) Heavy chain complementary determination region 2 (HCDR2), which contains an amino acid sequence, at least 95% of SEQ ID NO: 78; C). A heavy chain complementary determination region 3 (HCDR3) comprising a complete amino acid sequence having the same at least 95% of SEQ ID NO: 80; D) Light Chain Complementary Determination Region 1 (LCDR1), which comprises an amino acid sequence, which At least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 86; f) a light chain Complementary determination region 3 (LCDR3) contains at least 95% of the same amino acid sequence as SEQ ID NO: 88. The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (as SEQ ID NO: 755).","238, 755"
"Specific binding of the antibody diagnosis or antigen-substrate binding fragment of HPCSK9, which specifically binds to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95 of SEQ ID NO: 76.%; B) has a heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having the same 95% identical to SEQ ID NO: 78; C) contains heavy chain complementary determination regions 3 (HCDR3), including amino acidsSequence, which is exactly the same amino acid sequence as SEQ ID NO: 80.D) A light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2), which comprises an amino acid sequenceIt is at least 95% of SEQ ID NO: 86; F) A light chain complementary determination region 3 (LCDR3) comprising any of the same amino acid sequences as SEQ ID NO: 88. 2. Claim 1The antibody of the antibody or antigen binding fragment, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) heavy chain complementary determination region 1 (HCDR1), which contains the same amino acid sequence as SEQ ID NO: 76 and is not the same 95%; b) one heavyChain Complementary Determination Region 2 (HCDR2) contains an amino acid substitution sequence having the same at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing abdominal amino acid sequences, whichSEQ ID NO: 6 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) containing an amino acid sequence expansion, which is the same as at least 95% of SEQ ID NO: 84; E) in structureThe light chain complementary determination region 2 (LCDR2) comprises an amino acid sequence having the same at least 95%; F) Light chain complementary determination region 3 (LCDR3) as the SEQ ID NO: 86, which comprises a substantially amino acid sequence with SEQ ID NO: 88 The same at least 95% is the same. 2.The antibody or antigen binding fragment of the antibody according to claim 1 contains an epitope of the antibody or antigen binding fragment of the antibody comprises an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"An antibody or antigen binding fragment comprising an antibody or antibody, which specifically binds to HPCSK9, including: a) heavy chain complementary determination region 1 (HCDR1), which comprises an amino acid sequence unit, at least 95% of the same similar to SEQ ID NO : 76; add B) Similar heavy chain complementary determination regions 2 (HCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 78; c) a heavy chain complementary tag determination region 3 (HCDR3) It comprises at least 95% of the amino acid sequence, which is the same as SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as SEQ ID NO: 84 at least 95%. (e) a light chain complementary determination region 2 (LCDR2) comprising an amino acid sequence having at least 95%; F), at least 95%; f) a light chain complementary determination region 3 (LCDR3), The same amino acid sequence containing at least 95% is the same as SEQ ID NO: 80 88. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specific binds to HPCSK9, including: a) heavy chain complementary determination region 1 (HCDR1), which comprises at least 95%, the same amino acid sequence as SEQ ID NO: 76; b) The corresponding heavy chain complementDetermining region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; AC), a heavy chain complementary determination region 3 (HCDR3), contains at least 95% and SEQ ID NO: 480 The same basic amino acid sequence; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2 (LCDR2), which contains at least 95% of the same amino acid DNA sequence; F) a light chain complementary determination region 3 (LCDR3) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 88.2. Antibody or antigen binding fragment of the antibody according to claim 1, wherein the antigen binding fragment of the antibody itself or antibody binds to epitopes repeating, the epitope repeats the amino acid sequence residue 238 containing HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies specifically bind to HPCSK9 include: a) Heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ IC ID NO: 76; b) heavy chainComplementary determination region 2 (HCDR2) contains at least 95% or the same amino acid sequence as SEQ ID NO: 78; c) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 84; E) a light chain complementary determination region 2(LCDR2), which comprises at least 95% of the same active amino acid sequence; and 5 F) optical cross chain complementary determination region 3 (LCDR3), which comprises an amino acid sequence, which is the same as SEQ ID NO: 88.Amino acid sequence.Name 2. The antibody or antigen binding fragment of the antibody according to claim 1 includes an epitope in which a third antibody or antigen binding fragment 218 comprising HPCSK9 is combined with an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibodies or antigen-binding fragments that specifically bind to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is at least 95% of SEQ ID NO: 76; b) Heavy chainComplementary determination region 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3), which comprises an amino acid sequence, which is with existing SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising at least 95% identical amino acid sequence, i.e., SEQ ID NO: 84; E), in addition, a light chain containing a separate amino acid sequenceComplementary determination region 2 (LCDR2), which is the same as at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) comprising at least 95%, the same amino acid sequence as SEQ ID NO: 88..2.The claim 1 of the antibody or antigen binding fragment, wherein the antibody drug or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b)Chain Complementary Determination Region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; C) Heavy chain complementary determination region 3 (standard HCDR3) containing an amino acid sequence, at least 95% The same SEQ ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) Novel chain complementary analysis determined region2 (LCDR2) Further, its overall amino acid sequence, which is the same as at least 95%; 8 and f) of SEQ ID NO: 86; 8 and f) a light chain complementary determination region 3 (LCDR3) contains at least 95% and SEQ ID NO:88 The same amino acid sequence. 2.The antibody or antigen binding fragment residue of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 of HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or specific antigen binding fragment of the antibody of HPCSK9 was identified, including: or a) Heavy chain antigen complementarity determination region 1 (HCDR1), which comprises an amino acid sequence, which is the same as at least 95% as SEQ ID NO: 76 The heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence having at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) containing an amino acid sequence, It is at least 95% of the SEQ IV ID NO: 80; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) one The light chain complementary determination region 2 (LCDR2) contains an amino acid sequence having the same specificity of at least 95%, and the complement SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% The same amino acid sequence as SEQ ID NO: 88.12. The antibody or antigen binding fragment of claim 1 wherein the antibody or antigen-specific binding fragment of the antibody comprises an epitope comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"Antibody or antigen-binding fragment specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) Chain complementary determination region 2 (HCDR2) contains an amino acid sequence having the same at least 95% of SEQ ID NO: 78; also c) a basic heavy chain chain complementary determination region 3 (HCDR3), which comprises an amino acid sequence, At least 95% of SEQ ID NO: 80; D) a light chain complementary horizontal determination region 1 (LCDR1) comprising at least 95% of the same amino acid sequence as SEQ ID NO: 84; E) In addition, simple light Chain Chain Complementary Determination Region 2 (LCDR2) contains an external amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which comprises an amino acid sequence, each of which Amino acid sequence is 95% of SEQ ID NO: 88. The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"For antibodies or antigen binding fragments specific binding HPCSK9, including: a) Heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 76; b) comprising amino acid sequencesHeavy chain complementary determination region 2 (HCDR2), which is the same amino acid sequence as SEQ ID NO: 78; plus C) heavy chain complementary determination region 3 (HCDR3), which comprises an amino acid sequence, which is the same as at least 95% of SEQ ID NO.D) A light chain complementary determination region 1 (LCDR1) comprising an amino acid recognition sequence, which is the same as at least 95% of SEQ ID NO: 84; e) a light chain complementary determination region 2 (LCDR2), which containsAmino acid identification sequence, which is the same as at least 95% of SEQ ID NO: 86; Figures 6 and f) 6 and f) a light chain complementary determination region 3 (LCDR3) containing an amino acid sequence, which is associated with SEQ ID NO: 88At least 95% .2.The antibody or antigen binding fragment comprises the antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen-binding fragment specifically binding to HPCSK9, generally comprising: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 76; b) heavy chain complementary determination regions2 (SR HCDR2), which comprises at least 95% of the amino acid sequence, the amino acid sequence is the same as SEQ Sr ID NO: 78; B C) Heavy chain complementary determination region 3 (HCDR3), which comprises a amino acid sequence sequence, at least with SEQ IDNO: 80 is the same 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence having the same at least 95% of SEQ SD ID NO: 84; E) a light chain complementary region2 (LCDR2) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 86; F) Light chain complementary determination region 3 (LCDR3), which comprises at least 95%, the same amino acid as SEQ ID NO: 85 88.Sequence. 2.The antibody or antigen binding fragment of the antibody or antibody according to claim 1, wherein the antibody or antigen binding fragment of the antibody binds to an epitope comprising an amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen-binding fragment of HPCSK9 is most specific, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising at least 95% of the same amino acid sequence as AMA SEQ ID NO: 76; b) Heavy chain complementDetermination of region 2 (HCDR2) contains an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region 3 (HCDR3) comprising an amino acid sequence, which may be with SEQ ID NO: 80 The same at least 95%; D) A simple light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) a light chain complementary elementDetermining region 2 (LCDR2) contains at least 95% of the same amino acid sequence as the SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% identical to SEQ ID NO: 88.Amino acid sequence.The antibody or antigen-binding fragment of the antibody according to claim 1, wherein the antibody or antigen binding fragment of the identified antibody binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID IP NO: 755).","238, 755"
"Antibodies or antigen binding fragments of antibodies, which specifically binds to HPCSK9, including: a), in the heavy chain complementary determination region 1 (HCDR1), the heavy chain complementary region 1 (HCDR1) comprises an amino acid substrate sequence, The amino acid substrate sequence as the amino acid substrate sequence is the same as the SEQ ID NO: 76; B) Heavy chain complementary determination region 2 (HCDR2) comprising an amino acid sequence, at least 95% Same SEQ ID NO: 78; C) A short heavy chain complementary determination region indicia 3 (HCDR3) comprising an amino acid sequence having the same at least 95% of SEQ ID NO: 80; D) A light chain complementary determination harvest region 1 (LCDR1), which contains amino acids The sequence is at least 95% of SEQ ID NO: 84; e) a light chain-specific complementary determination region 2 (LCDR2) comprising an amino acid sequence having the same at least 95% as SEQ ID NO: 86; F A light chain complementary determination region 3 (LCDR3) comprising an amino acid sequence having at least 95% of SEQ ID NO: 88. 2. Antibody or antigen binding fragment of claim 1 wherein the antibody or antigen binding fragment of the antibody binds to an epitope fragment comprising the amino acid residue 238 of HPCSK9 (SEQ ID NO: 755).","238, 755"
"Specific binding to HPCSK9 antibodies or antigen-ligand binders, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising an amino acid sequence having the same at least 95% as SEQ ID NO: 76; b)Heavy chain complementary determination region 2 (HCDR2) contains an amino acid sequence which is the same as at least 95% of SEQ ID NO: 78; C) Heavy Chain Complementary Determination Region 3 (HCDR3) typically comprises an amino acid sequence, which is associated with SEQ ID NO: 80 The same at least 95%; D) a light chain complementary determination region 1 (LCDR1) comprising an amino acid sequence, which is the same as at least 95% of SEQ ID NO: 84; E) Light chain complementary determination region 2 (LCDR2) typically comprises at least 95% of SEQ ID NO: 86; F) a light chain complementary determination region 3 (LCDR3) having a light chain complementary determination region 3 (LCDR3), which comprises at least 95% of the same amino acid sequence as SEQ ID NO: 88.The antibody or antigen binding fragment of the antibody according to claim 1, wherein the antibody itself or antibody antigen binding DNA fragment combines an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
"The antibody or antigen binding fragment of the antibody specifically binding to HPCSK9, including: a) a heavy chain complementary determination region 1 (HCDR1) comprising a amino acid sequence, at least 95% of SEQ ID NO: 76; b) heavy chain complementary determinationRegion 2 (HCDR2), which comprises an amino acid sequence having the same at least 95% of SEQ ID NO: 78; C) a heavy chain complementary determination region piece 3 (HCDR3) containing an amino acid sequence, which is usually with SEQ ID NO: 80 The same at least 95%; D) a light chain mutual feedstock determination region 1 (LCDR1) containing at least 95% of the same independent amino acid sequence as SEQ ID NO: 84; E) a light chainComplementary determination region 2 (LCDR2) contains an amino acid sequence which is the same as at least 95% of SEQ ID NO: 86; and is F) a light chain complementary determination region 3 (LCDR3), which contains at least 95% and SEQ ID.NO: 88 The same amino acid sequence. 2.The antibody or antigen-gel binding fragment of the antibody according to claim 1, wherein the antibody of the antibody or antigen binding peptide fragment 242 binds to an epitope of the amino acid residue 238 comprising HPCSK9 (SEQ ID NO: 755).","238, 755"
